| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1584 | 2017 |
| Erdafitinib in locally advanced or metastatic urothelial carcinoma Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ... New England Journal of Medicine 381 (4), 338-348, 2019 | 1095 | 2019 |
| Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ... New England Journal of Medicine 381 (25), 2403-2415, 2019 | 767 | 2019 |
| Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre … J Garcia-Donas, E Esteban, LJ Leandro-García, DE Castellano, ... The lancet oncology 12 (12), 1143-1150, 2011 | 289 | 2011 |
| Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, ... JAMA oncology 3 (12), e173290-e173290, 2017 | 279 | 2017 |
| Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity S Leskelä, C Jara, LJ Leandro-Garcia, A Martinez, J Garcia-Donas, ... The pharmacogenomics journal 11 (2), 121-129, 2011 | 161 | 2011 |
| A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li–Fraumeni-like families O Calvete, P Martinez, P Garcia-Pavia, C Benitez-Buelga, ... Nature communications 6 (1), 8383, 2015 | 158 | 2015 |
| Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis I Diaz-Padilla, N Romero, E Amir, X Matias-Guiu, E Vilar, F Muggia, ... Critical reviews in oncology/hematology 88 (1), 154-167, 2013 | 138 | 2013 |
| Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) E Grande, J Capdevila, D Castellano, A Teulé, I Durán, J Fuster, I Sevilla, ... Annals of oncology 26 (9), 1987-1993, 2015 | 135 | 2015 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 122 | 2022 |
| Prognostic gene expression signature for high-grade serous ovarian cancer J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, ... Annals of oncology 31 (9), 1240-1250, 2020 | 104 | 2020 |
| Strategies to design clinical studies to identify predictive biomarkers in cancer research JL Perez-Gracia, MF Sanmamed, A Bosch, A Patiño-Garcia, KA Schalper, ... Cancer Treatment Reviews 53, 79-97, 2017 | 103 | 2017 |
| Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma C Prior, JL Perez-Gracia, J Garcia-Donas, C Rodriguez-Antona, ... PloS one 9 (1), e86263, 2014 | 101 | 2014 |
| Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled … JA Ledermann, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet Oncology 21 (5), 710-722, 2020 | 100 | 2020 |
| CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma MHM Diekstra, JJ Swen, E Boven, D Castellano, H Gelderblom, ... European urology 68 (4), 621-629, 2015 | 95 | 2015 |
| Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study AO Siefker-Radtke, A Necchi, SH Park, J García-Donas, RA Huddart, ... The lancet oncology 23 (2), 248-258, 2022 | 90 | 2022 |
| Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma J Garcia-Donas, LJ Leandro-Garcia, AG Del Alba, M Morente, I Alemany, ... Annals of oncology 24 (9), 2409-2414, 2013 | 90 | 2013 |
| Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy M Apellániz-Ruiz, MY Lee, L Sánchez-Barroso, G Gutiérrez-Gutiérrez, ... Clinical Cancer Research 21 (2), 322-328, 2015 | 79 | 2015 |
| Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB L Minig, MG Patrono, N Romero, JFR Moreno, J Garcia-Donas World journal of clinical oncology 5 (2), 86, 2014 | 76 | 2014 |
| Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study PF Rambau, RA Vierkant, MP Intermaggio, LE Kelemen, MT Goodman, ... The Journal of Pathology: Clinical Research 4 (4), 250-261, 2018 | 75 | 2018 |
